Cargando…
Evaluation of factors affecting epidermal growth factor receptor tyrosine kinase inhibitor-induced hepatotoxicity in Japanese patients with non-small cell lung cancer: a two-center retrospective study
BACKGROUND: Gefitinib and erlotinib, are epidermal growth factor receptor tyrosine kinase inhibitors, and are currently recommended for non-small cell lung cancer stage IV in the elderly and in patients with decreased performance status in the Japanese Lung Cancer Society Guideline, but they occasio...
Autores principales: | Nagai, Hirofumi, Shimada, Tsutomu, Takahashi, Yoshimitsu, Nishikawa, Mikako, Tozuka, Hiroyuki, Yamamoto, Yasuto, Niwa, Osamu, Takahara, Yutaka, Fujita, Arimi, Nagase, Katsuhiko, Kasahara, Kazuo, Yano, Seiji, Sai, Yoshimichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714078/ https://www.ncbi.nlm.nih.gov/pubmed/36451213 http://dx.doi.org/10.1186/s40780-022-00258-7 |
Ejemplares similares
-
Incidence and risk factors of neonatal hypoglycemia after ritodrine therapy in premature labor: a retrospective cohort study
por: Shimokawa, Shoko, et al.
Publicado: (2019) -
Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double‐positive lung cancer
por: Takeuchi, Shinji, et al.
Publicado: (2020) -
Limited Impact of Murine Placental MDR1 on Fetal Exposure of Certain Drugs Explained by Bypass Transfer Between Adjacent Syncytiotrophoblast Layers
por: Fujita, Arimi, et al.
Publicado: (2022) -
Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib‐resistance of EML4‐ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors
por: Taniguchi, Hirokazu, et al.
Publicado: (2016) -
Assessment of epidermal growth factor receptor status in glioblastomas
por: Zhu, Hui-Jun, et al.
Publicado: (2013)